Interleukin-2 receptor blockade with humanized monoclonal antibody for solid organ transplantation

Bibliography

• Robb RJ, Munck A, Smith KA. T cell growth factor receptors quantitation, specificity, and biological relevance. J Exp Med 1981;154(5):1455-74
   PubMed Web of Science ®Google Scholar
• Queen C, Schneider WP, Selick HE, A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 1989;10(24):10029-33
   Google Scholar
• Uchiyama T, Broder S, Waldmann TA. A monoclonal antibody (anti-tac) reactive with activated and functionally mature human T cells. I. Production of anti-tac monoclonal antibody and distribution of tac (+) cells. J Immunol 1981;126(4):1393-7
   PubMedGoogle Scholar
• Depper JM, Leonard WJ, Robb RJ, Blockade of the interleukin-2 receptor by anti-tac antibody: Inhibition of human lymphocyte activation. J Immunol 1983;131(2):690-6
   PubMed Web of Science ®Google Scholar
• Vincenti F, Pace D, Birnbaum J, Lantz M. Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation. Am J Transplant 2003;3(1):50-2
   PubMed Web of Science ®Google Scholar
• Vincenti F, Kirkman R, Light S, Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab triple therapy study group. N Engl J Med 1998;338(3):161-5
   PubMed Web of Science ®Google Scholar
• Zenapax product monograph. F. Hoffmann-La Roche (Basel), Basel, Switzeland; 1997
   Google Scholar
• ter Meulen CG, Baan CC, Hene RJ, Two doses of daclizumab are sufficient for prolonged interleukin-2Ralpha chain blockade. Transplantation 2001;72(10):1709-10
   PubMed Web of Science ®Google Scholar
• Stratta RJ, Alloway RR, Lo A, Hodge E. Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study. Transplantation 2003;75(8):1260-6
   PubMed Web of Science ®Google Scholar
• Eckhoff DE, McGuire B, Sellers M, The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients. Transplantation 2000;69(9):1867-72
   PubMed Web of Science ®Google Scholar
• Jain A, Valentini RP, Gruber SA, Two-dose daclizumab induction in pediatric renal transplantation. Pediatr Transplant 2009;13(4):490-4
   PubMed Web of Science ®Google Scholar
• Pham K, Kraft K, Thielke J, Limited-dose daclizumab versus basiliximab: a comparison of cost and efficacy in preventing acute rejection. Transplant Proc 2005;37(2):899-902
   PubMed Web of Science ®Google Scholar
• Joyal D, Cantarovich M, Cecere R, Giannetti N. Early experience with two-dose daclizumab in the prevention of acute rejection in cardiac transplantation. Clin Transplant 2004;18(5):493-6
   PubMed Web of Science ®Google Scholar
• Ortiz V, Almenar L, Martinez-Dolz L, Induction therapy with daclizumab in heart transplantation–how many doses? Transplant Proc 2006;38(8):2541-3
   PubMed Web of Science ®Google Scholar
• Koch M, Niemeyer G, Patel I, Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation. Transplantation 2002;73(10):1640-6
   PubMed Web of Science ®Google Scholar
• Figueras J, Bernardos A, Prieto M, Steroid-free regimen with daclizumab, mycophenolate mofetil, and tacrolimus in liver transplant recipients. Transplant Proc 2002;34(5):1511-3
   PubMed Web of Science ®Google Scholar
• Niemeyer G, Koch M, Light S, Long-term safety, tolerability and efficacy of daclizumab (zenapax) in a two-dose regimen in liver transplant recipients. Am J Transplant 2002;2(5):454-60
   PubMed Web of Science ®Google Scholar
• Nashan B, Light S, Hardie IR, Reduction of acute renal allograft rejection by daclizumab. Daclizumab double therapy study group. Transplantation 1999;67(1):110-5
   PubMed Web of Science ®Google Scholar
• Ciancio G, Burke GW, Suzart K, Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation 2002;73(7):1100-6
   PubMed Web of Science ®Google Scholar
• Abu-Elmagd K, Fung J, McGhee W, The efficacy of daclizumab for intestinal transplantation: preliminary report. Transplant Proc 2000;32(6):1195-6
   PubMed Web of Science ®Google Scholar
• Carreno MR, Kato T, Weppler D, Induction therapy with daclizumab as part of the immunosuppressive regimen in human small bowel and multiorgan transplants. Transplant Proc 2001;33(1-2):1015-7
   PubMed Web of Science ®Google Scholar
• Beniaminovitz A, Itescu S, Lietz K, Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Eng J Med 2000;342(9):613-9
   PubMed Web of Science ®Google Scholar
• Hershberger RE, Starling RC, Eisen HJ, Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 2005;352(26):2705-13
   PubMed Web of Science ®Google Scholar
• Kobashigawa J, David K, Morris J, Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids. Transplant Proc 2005;37(2):1333-9
   PubMed Web of Science ®Google Scholar
• Brock MV, Borja MC, Ferber L, Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab. J Heart Lung Transplant 2001;20(12):1282-90
   PubMed Web of Science ®Google Scholar
• Garrity ER Jr, Villanueva J, Bhorade SM, Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody. Transplantation 2001;71(6):773-7
   PubMed Web of Science ®Google Scholar
• Grego K, Arnol M, Bren AF, Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients. Transplant Proc 2007;39(10):3093-7
   PubMed Web of Science ®Google Scholar
• Nair MP, Nampoory MR, Johny KV, Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients. Transplant Proc 2001;33(5):2767-9
   PubMed Web of Science ®Google Scholar
• Lin M, Ming A, Zhao M. Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study. Clin transplant 2006;20(3):325-9
   PubMed Web of Science ®Google Scholar
• Abou-Jaoude MM, Ghantous I, Najm R, Daclizumab versus anti-thymocyte globulin-fresenius as induction therapy for low-risk kidney transplant recipients. Transplant proc 2003;35(7):2731-2
   PubMed Web of Science ®Google Scholar
• Alloway RR, Hanaway MJ, Trofe J, A prospective, pilot study of early corticosteroid cessation in high-immunologic-risk patients: the Cincinnati experience. Transplant Proc 2005;37(2):802-3
   PubMed Web of Science ®Google Scholar
• Vo AA, Toyoda M, Peng A, Effect of induction therapy protocols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IVIG. Am J Transplant 2006;6(10):2384-90
   PubMed Web of Science ®Google Scholar
• Kim MJ, Tsinalis D, Franz S, ATG-fresenius or daclizumab induction therapy in immunologically high risk kidney recipients: a prospective randomized pilot trial. Ann Transplant 2008;13(4):21-7
   PubMed Web of Science ®Google Scholar
• Noel C, Abramowicz D, Durand D, Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol 2009;20(6):1385-92
   PubMed Web of Science ®Google Scholar
• Lischke R, Simonek J, Davidova R, Induction therapy in lung transplantation: initial single-center experience comparing daclizumab and antithymocyte globulin. Transplant Proc 2007;39(1):205-12
   PubMed Web of Science ®Google Scholar
• Mullen JC, Oreopoulos A, Lien DC, A randomized, controlled trial of daclizumab vs anti-thymocyte globulin induction for lung transplantation. J Heart Lung Transplant 2007;26(5):504-10
   PubMed Web of Science ®Google Scholar
• Ciancio G, Burke GW, Gaynor JJ, A randomized trial of thymoglobulin vs alemtuzumab (with lower dose maintenance immunosuppression) vs daclizumab in renal transplantation at 24 months of follow-up. Clin transplant 2008;22(2):200-10
   PubMed Web of Science ®Google Scholar
• Garcia M, Weppler D, Mittal N, Campath-1H immunosuppressive therapy reduces incidence and intensity of acute rejection in intestinal and multivisceral transplantation. Transplant Proc 2004;36(2):323-4
   PubMed Web of Science ®Google Scholar
• Lauro A, Amaduzzi A, Dazzi A, Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: a comparison of two different regimens on 29 recipients during the early post-operative period. Dig Liver Dis 2007;39(3):253-6
   PubMedGoogle Scholar
• Zanfi C, Lauro A, Cescon M, Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period. Transplant Proc 2010;42(1):35-8
   PubMed Web of Science ®Google Scholar
• Lacha J, Simova M, Noskova L, Zenapax versus OKT-3 prophylaxis in immunologically high-risk kidney transplant recipients. Transplant Proc 2001;33(3):2273-4
   PubMed Web of Science ®Google Scholar
• Chin C, Pittson S, Luikart H, Induction therapy for pediatric and adult heart transplantation: comparison between OKT3 and daclizumab. Transplantation 2005;80(4):477-81
   PubMed Web of Science ®Google Scholar
• Campos A, Lage E, Hinojosa R, Comparative study of muromonab-CD3 (OKT3) versus daclizumab (zenapax) in cardiac transplantation at our center. Transplant Proc 2005;37(3):1548-9
   PubMed Web of Science ®Google Scholar
• Wiland AM, Philosophe B. Daclizumab induction in solid organ transplantation. Expert Opin Biol Ther 2004;4(5):729-40
   PubMed Web of Science ®Google Scholar
• Mottershead M, Neuberger J. Daclizumab. Expert Opin Biol Ther 2007;7(10):1583-96
   PubMed Web of Science ®Google Scholar
• Kato T, Gaynor JJ, Yoshida H, Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. Transplantation 2007;84(7):829-35
   PubMed Web of Science ®Google Scholar
• Klintmalm GB, Washburn WK, Rudich SM, Corticosteroid-free immunosuppression with daclizumab in HCV+ liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl 2007;13(11):1521-31
   PubMed Web of Science ®Google Scholar
• Neuberger JM, Mamelok RD, Neuhaus P, Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the ‘ReSpECT’ study. Am J Transplant 2009;9(2):327-36
   PubMed Web of Science ®Google Scholar
• Kirk AD, Cherikh WS, Ring M, Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007;7(11):2619-25
   PubMed Web of Science ®Google Scholar